Pfizer Europe MA EEIG
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference b77f7141c9
Drug names22First applicant · distinct drug namesAcceptance records234First applicant · distinct acceptance numbersUnder-review numbers17First applicant · current under-review listCo-applicant records10Subsequent applicant only · separate count
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/11 06:42.
Drug filings
234 acceptance records as first applicant, grouped into 22 source drug names. Source data as of 2026/11/11 06:42.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
Voriconazole for Injection 12 records · Latest accepted 2026/11/09
Import re-registration · 2Supplement · 10
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2600296 | Import re-registration | 2026/11/09 | Pfizer Europe MA EEIG; Pharmacia & Upjohn Company LLC; Pfizer Investment CO. Ltd. | CDE ↗ |
| JYHB2600202 | Supplement | 2026/04/02 | Pfizer Europe MA EEIG; Pharmacia & Upjohn Company LLC | CDE ↗ |
| JYHB2500566 | Supplement | 2025/10/29 | Pfizer Europe MA EEIG; Pharmacia & Upjohn Company LLC | CDE ↗ |
| JYHB2400066 | Supplement | 2024/02/05 | Pfizer Europe MA EEIG; Pharmacia & Upjohn Company LLC | CDE ↗ |
| JYHB2300579 | Supplement | 2023/10/17 | Pfizer Europe MA EEIG; Pharmacia & Upjohn Company LLC | CDE ↗ |
| JYHB2300016 | Supplement | 2023/01/06 | Pfizer Europe MA EEIG; Pharmacia & Upjohn Company LLC | CDE ↗ |
| JYHB2200350 | Supplement | 2022/07/08 | Pfizer Europe MA EEIG; Pharmacia & Upjohn Company LLC | CDE ↗ |
| JYHZ2200156 | Import re-registration | 2022/06/20 | Pfizer Europe MA EEIG; Pharmacia & Upjohn Company LLC; Pfizer Investment CO. Ltd. | CDE ↗ |
| JYHB2101601 | Supplement | 2021/12/22 | Pfizer Europe MA EEIG; Pharmacia & Upjohn Company LLC | CDE ↗ |
| JYHB2101151 | Supplement | 2021/05/28 | Pfizer Europe MA EEIG; Pharmacia & Upjohn Company LLC | CDE ↗ |
| JYHB2100069 | Supplement | 2021/01/21 | Pfizer Europe MA EEIG; Pharmacia & Upjohn Company | CDE ↗ |
| JYHB2002746 | Supplement | 2021/01/01 | Pfizer Europe MA EEIG; Pharmacia & Upjohn Company | CDE ↗ |
No verified English name 4 records · Latest accepted 2026/09/28
Import re-registration · 2Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2600244 | Import re-registration | 2026/09/28 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH; Pizer Investment Co. Ltd. | CDE ↗ |
| JYHZ2600243 | Import re-registration | 2026/09/28 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH; Pizer Investment Co. Ltd. | CDE ↗ |
| JYHB2600314 | Supplement | 2026/06/10 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| JYHB2600313 | Supplement | 2026/06/10 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
Tofacitinib Citrate Tablets 11 records · Latest accepted 2026/08/31
Supplement · 7Import re-registration · 2Import · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600502 | Supplement | 2026/08/31 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| JYHB2600271 | Supplement | 2026/05/14 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| JYHZ2500276 | Import re-registration | 2025/12/06 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH; Pfizer Investment Co. Ltd | CDE ↗ |
| JYHB2500483 | Supplement | 2025/09/12 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| JYHB2400497 | Supplement | 2024/09/15 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| JYHB2200454 | Supplement | 2022/08/16 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| JYHB2200108 | Supplement | 2022/03/02 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| JXHS2200002 | Import | 2022/01/06 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH; Pfizer Investment Co. Ltd | CDE ↗ |
| JYHB2101098 | Supplement | 2021/05/17 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| JYHZ2100069 | Import re-registration | 2021/04/01 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| JXHS2100011 | Import | 2021/01/27 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
No verified English name 19 records · Latest accepted 2026/08/24
Supplement · 14Import · 3Import re-registration · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYSB2600234 | Supplement | 2026/08/24 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals Unlimited Company | CDE ↗ |
| JXSL2600227 | Import | 2026/08/24 | Pfizer Europe MA EEIG; Pfizer Investment CO. Ltd. | CDE ↗ |
| JYSZ2500023 | Import re-registration | 2025/08/08 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals; Pfizer Investment CO. Ltd. | CDE ↗ |
| JYSB2500123 | Supplement | 2025/05/28 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals | CDE ↗ |
| JYSB2500001 | Supplement | 2025/01/03 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals | CDE ↗ |
| JYSB2400239 | Supplement | 2024/11/08 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals | CDE ↗ |
| JXSL2400209 | Import | 2024/11/01 | Pfizer Europe MA EEIG; Pfizer Investment CO. Ltd. | CDE ↗ |
| JYSB2300226 | Supplement | 2023/12/29 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals | CDE ↗ |
| JYSB2300225 | Supplement | 2023/12/28 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals | CDE ↗ |
| JYSB2300174 | Supplement | 2023/10/11 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals | CDE ↗ |
| JYSB2300152 | Supplement | 2023/09/07 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals | CDE ↗ |
| JYSB2300062 | Supplement | 2023/04/10 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals | CDE ↗ |
| JYSB2300021 | Supplement | 2023/02/07 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals | CDE ↗ |
| JYSB2200173 | Supplement | 2022/09/09 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals | CDE ↗ |
| JYSB2200069 | Supplement | 2022/04/15 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals | CDE ↗ |
| JYSB2200042 | Supplement | 2022/03/16 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals | CDE ↗ |
| JYSB2101199 | Supplement | 2021/12/20 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals | CDE ↗ |
| JXSS2100019 | Import | 2021/02/24 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals | CDE ↗ |
| JYSZ2100004 | Import re-registration | 2021/02/06 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals | CDE ↗ |
No verified English name 5 records · Latest accepted 2026/08/24
Import · 3Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2600226 | Import | 2026/08/24 | Pfizer Europe MA EEIG; Pfizer Investment CO. Ltd. | CDE ↗ |
| JXSL2600221 | Import | 2026/08/21 | Pfizer Europe MA EEIG; Pfizer Investment CO. Ltd. | CDE ↗ |
| JXSB2600028 | Supplement | 2026/02/14 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals | CDE ↗ |
| JXSB2500046 | Supplement | 2025/05/27 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals | CDE ↗ |
| JXSL2400166 | Import | 2024/09/13 | Pfizer Europe MA EEIG; Pfizer Investment CO. Ltd. | CDE ↗ |
Parecoxib Sodium for Injection 6 records · Latest accepted 2026/08/12
Import re-registration · 3Supplement · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2600191 | Import re-registration | 2026/08/12 | Pfizer Europe MA EEIG; Pharmacia & Upjohn Company LLC; Pfizer Investment CO. Ltd. | CDE ↗ |
| JYHB2400224 | Supplement | 2024/05/21 | Pfizer Europe MA EEIG; Pharmacia & Upjohn Company LLC | CDE ↗ |
| JYHB2400110 | Supplement | 2024/02/29 | Pfizer Europe MA EEIG; Pharmacia & Upjohn Company LLC | CDE ↗ |
| JYHZ2100653 | Import re-registration | 2021/10/14 | Pfizer Europe MA EEIG; Pharmacia & Upjohn Company LLC; Pfizer Investment CO. Ltd. | CDE ↗ |
| JYHZ2100652 | Import re-registration | 2021/10/14 | Pfizer Europe MA EEIG; Pharmacia & Upjohn Company LLC; Pfizer Investment CO. Ltd. | CDE ↗ |
| JYHB2100194 | Supplement | 2021/03/12 | Pfizer Europe MA EEIG; Pharmacia & Upjohn Company LLC | CDE ↗ |
No verified English name 10 records · Latest accepted 2026/06/22
Import · 10
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHS2600071 | Import | 2026/06/22 | Pfizer Europe MA EEIG; Excella GmbH & Co. KG; Pfizer Investment CO. Ltd. | CDE ↗ |
| JXHS2600070 | Import | 2026/06/22 | Pfizer Europe MA EEIG; Excella GmbH & Co. KG; Pfizer Investment CO. Ltd. | CDE ↗ |
| JXHS2600069 | Import | 2026/06/22 | Pfizer Europe MA EEIG; Excella GmbH & Co. KG; Pfizer Investment CO. Ltd. | CDE ↗ |
| JXHS2600068 | Import | 2026/06/22 | Pfizer Europe MA EEIG; Excella GmbH & Co. KG; Pfizer Investment CO. Ltd. | CDE ↗ |
| JXHS2500047 | Import | 2025/04/16 | Pfizer Europe MA EEIG; Excella GmbH & Co. KG; Pfizer Investment CO. Ltd. | CDE ↗ |
| JXHS2500046 | Import | 2025/04/16 | Pfizer Europe MA EEIG; Excella GmbH & Co. KG; Pfizer Investment CO. Ltd. | CDE ↗ |
| JXHS2300032 | Import | 2023/04/01 | Pfizer Europe MA EEIG; Excella GmbH & Co. KG; Pfizer Investment CO. Ltd. | CDE ↗ |
| JXHS2300031 | Import | 2023/04/01 | Pfizer Europe MA EEIG; Excella GmbH & Co. KG; Pfizer Investment CO. Ltd. | CDE ↗ |
| JXHS2300030 | Import | 2023/04/01 | Pfizer Europe MA EEIG; Excella GmbH & Co. KG; Pfizer Investment CO. Ltd. | CDE ↗ |
| JXHS2300029 | Import | 2023/04/01 | Pfizer Europe MA EEIG; Excella GmbH & Co. KG; Pfizer Investment CO. Ltd. | CDE ↗ |
Voriconazole for Oral Suspension 8 records · Latest accepted 2026/06/08
Supplement · 7Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600310 | Supplement | 2026/06/08 | Pfizer Europe MA EEIG; Fareva Amboise | CDE ↗ |
| JYHB2300580 | Supplement | 2023/10/17 | Pfizer Europe MA EEIG; Fareva Amboise | CDE ↗ |
| JYHB2300046 | Supplement | 2023/01/13 | Pfizer Europe MA EEIG; Fareva Amboise | CDE ↗ |
| JYHZ2300020 | Import re-registration | 2023/01/11 | Pfizer Europe MA EEIG; Fareva Amboise; Pfizer Investment CO. Ltd. | CDE ↗ |
| JYHB2200351 | Supplement | 2022/07/08 | Pfizer Europe MA EEIG; Fareva Amboise | CDE ↗ |
| JYHB2101600 | Supplement | 2021/12/22 | Pfizer Europe MA EEIG; Fareva Amboise | CDE ↗ |
| JYHB2101148 | Supplement | 2021/05/31 | Pfizer Europe MA EEIG; Fareva Amboise | CDE ↗ |
| JYHB2100064 | Supplement | 2021/01/21 | Pfizer Europe MA EEIG; Fareva Amboise | CDE ↗ |
No verified English name 3 records · Latest accepted 2026/05/08
Supplement · 2Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600251 | Supplement | 2026/05/08 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals Unlimited Company | CDE ↗ |
| JYHZ2300042 | Import re-registration | 2023/01/31 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals; Pfizer Investment CO. Ltd. | CDE ↗ |
| JYHB2200392 | Supplement | 2022/07/26 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals | CDE ↗ |
Voriconazole Tablets 20 records · Latest accepted 2026/04/02
Supplement · 18Import re-registration · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600201 | Supplement | 2026/04/02 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHB2600200 | Supplement | 2026/04/02 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHB2500565 | Supplement | 2025/10/28 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHB2500564 | Supplement | 2025/10/28 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHB2400068 | Supplement | 2024/02/05 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHB2400067 | Supplement | 2024/02/05 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHB2300587 | Supplement | 2023/10/19 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHB2300586 | Supplement | 2023/10/19 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHZ2300232 | Import re-registration | 2023/05/19 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l.; Pfizer Investment Co. Ltd. | CDE ↗ |
| JYHZ2300231 | Import re-registration | 2023/05/19 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l.; Pfizer Investment Co. Ltd. | CDE ↗ |
| JYHB2300022 | Supplement | 2023/01/07 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHB2300021 | Supplement | 2023/01/07 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHB2200353 | Supplement | 2022/07/08 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHB2200352 | Supplement | 2022/07/08 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHB2101603 | Supplement | 2021/12/22 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHB2101602 | Supplement | 2021/12/22 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHB2101150 | Supplement | 2021/05/28 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHB2101149 | Supplement | 2021/05/28 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHB2100003 | Supplement | 2021/01/06 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHB2100002 | Supplement | 2021/01/06 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
No verified English name 12 records · Latest accepted 2026/03/21
Supplement · 9Import re-registration · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600189 | Supplement | 2026/03/21 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHB2600188 | Supplement | 2026/03/21 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHB2600187 | Supplement | 2026/03/21 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHZ2200007 | Import re-registration | 2022/01/06 | Pfizer Europe MA EEIG; R-Pharm Germany GmbH; Pfizer Investment CO. Ltd. | CDE ↗ |
| JYHZ2200006 | Import re-registration | 2022/01/06 | Pfizer Europe MA EEIG; R-Pharm Germany GmbH; Pfizer Investment CO. Ltd. | CDE ↗ |
| JYHZ2200005 | Import re-registration | 2022/01/06 | Pfizer Europe MA EEIG; R-Pharm Germany GmbH; Pfizer Investment CO. Ltd. | CDE ↗ |
| JYHB2100229 | Supplement | 2021/03/31 | Pfizer Europe MA EEIG; R-Pharm Germany GmbH | CDE ↗ |
| JYHB2100228 | Supplement | 2021/03/31 | Pfizer Europe MA EEIG; R-Pharm Germany GmbH | CDE ↗ |
| JYHB2100227 | Supplement | 2021/03/31 | Pfizer Europe MA EEIG; R-Pharm Germany GmbH | CDE ↗ |
| JYHB2100118 | Supplement | 2021/02/03 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHB2100117 | Supplement | 2021/02/03 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| JYHB2100116 | Supplement | 2021/02/03 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
Tigecycline for Injection 3 records · Latest accepted 2026/02/27
Supplement · 2Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600122 | Supplement | 2026/02/27 | Pfizer Europe MA EEIG; Wyeth Lederle S.r.l. | CDE ↗ |
| JYHZ2500188 | Import re-registration | 2025/08/16 | Pfizer Europe MA EEIG; Wyeth Lederle S.r.l.; Pfizer Investment CO. Ltd. | CDE ↗ |
| JYHB2101307 | Supplement | 2021/08/12 | Pfizer Europe MA EEIG; Wyeth Lederle S.r.l. | CDE ↗ |
Tafamidis soft Capsules 6 records · Latest accepted 2026/01/06
Supplement · 5Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600018 | Supplement | 2026/01/06 | Pfizer Europe MA EEIG; Catalent Pharma Solutions LLC | CDE ↗ |
| JYHZ2400258 | Import re-registration | 2024/09/25 | Pfizer Europe MA EEIG; Catalent Pharma Solutions LLC; Pfizer Investment Co. Ltd. | CDE ↗ |
| JYHB2400268 | Supplement | 2024/06/06 | Pfizer Europe MA EEIG; Catalent Pharma Solutions LLC | CDE ↗ |
| JYHB2300535 | Supplement | 2023/09/18 | Pfizer Europe MA EEIG; Catalent Pharma Solutions LLC | CDE ↗ |
| JYHB2200070 | Supplement | 2022/02/09 | Pfizer Europe MA EEIG; Catalent Pharma Solutions LLC | CDE ↗ |
| JYHB2101395 | Supplement | 2021/09/08 | Pfizer Europe MA EEIG; Catalent Pharma Solutions LLC | CDE ↗ |
Palbociclib Capsules 24 records · Latest accepted 2025/12/02
Supplement · 21Import re-registration · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2500657 | Supplement | 2025/12/02 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| JYHB2500656 | Supplement | 2025/12/02 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| JYHB2500655 | Supplement | 2025/12/02 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| JYHB2400493 | Supplement | 2024/09/14 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg | CDE ↗ |
| JYHB2400492 | Supplement | 2024/09/14 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg | CDE ↗ |
| JYHB2400491 | Supplement | 2024/09/14 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg | CDE ↗ |
| JYHB2300655 | Supplement | 2023/11/16 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg | CDE ↗ |
| JYHB2300654 | Supplement | 2023/11/16 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg | CDE ↗ |
| JYHB2300653 | Supplement | 2023/11/16 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg | CDE ↗ |
| JYHB2300499 | Supplement | 2023/09/02 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg | CDE ↗ |
| JYHB2300498 | Supplement | 2023/09/02 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg | CDE ↗ |
| JYHB2300497 | Supplement | 2023/09/02 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg | CDE ↗ |
| JYHZ2300019 | Import re-registration | 2023/01/09 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg; Pfizer Investment CO. Ltd | CDE ↗ |
| JYHZ2300018 | Import re-registration | 2023/01/09 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg; Pfizer Investment CO. Ltd | CDE ↗ |
| JYHZ2300017 | Import re-registration | 2023/01/09 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg; Pfizer Investment CO. Ltd | CDE ↗ |
| JYHB2200415 | Supplement | 2022/08/11 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg | CDE ↗ |
| JYHB2200414 | Supplement | 2022/08/11 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg | CDE ↗ |
| JYHB2200413 | Supplement | 2022/08/11 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg | CDE ↗ |
| JYHB2101283 | Supplement | 2021/07/27 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg | CDE ↗ |
| JYHB2101282 | Supplement | 2021/07/27 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg | CDE ↗ |
| JYHB2101281 | Supplement | 2021/07/27 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg | CDE ↗ |
| JYHB2101136 | Supplement | 2021/05/26 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg | CDE ↗ |
| JYHB2101135 | Supplement | 2021/05/26 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg | CDE ↗ |
| JYHB2101134 | Supplement | 2021/05/26 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg | CDE ↗ |
No verified English name 28 records · Latest accepted 2025/10/21
Supplement · 24Import re-registration · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYSB2500251 | Supplement | 2025/10/21 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2500250 | Supplement | 2025/10/21 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2500249 | Supplement | 2025/10/21 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2500248 | Supplement | 2025/10/21 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2500026 | Supplement | 2025/02/08 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2500025 | Supplement | 2025/02/08 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2500024 | Supplement | 2025/02/08 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2500023 | Supplement | 2025/02/08 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2400158 | Supplement | 2024/07/16 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2400157 | Supplement | 2024/07/16 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2400156 | Supplement | 2024/07/16 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2400155 | Supplement | 2024/07/16 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSZ2200030 | Import re-registration | 2022/06/29 | Pfizer Europe MA EEIG; Wyeth Farma S.A.; Pfizer Investment CO. Ltd | CDE ↗ |
| JYSZ2200029 | Import re-registration | 2022/06/29 | Pfizer Europe MA EEIG; Wyeth Farma S.A.; Pfizer Investment CO. Ltd | CDE ↗ |
| JYSZ2200028 | Import re-registration | 2022/06/29 | Pfizer Europe MA EEIG; Wyeth Farma S.A.; Pfizer Investment CO. Ltd | CDE ↗ |
| JYSZ2200027 | Import re-registration | 2022/06/29 | Pfizer Europe MA EEIG; Wyeth Farma S.A.; Pfizer Investment CO. Ltd | CDE ↗ |
| JYSB2200095 | Supplement | 2022/06/09 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2200094 | Supplement | 2022/06/09 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2200093 | Supplement | 2022/06/09 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2200092 | Supplement | 2022/06/09 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2101172 | Supplement | 2021/11/25 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2101171 | Supplement | 2021/11/25 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2101170 | Supplement | 2021/11/25 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2101169 | Supplement | 2021/11/25 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2100027 | Supplement | 2021/01/22 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2100026 | Supplement | 2021/01/22 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2100025 | Supplement | 2021/01/22 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2100024 | Supplement | 2021/01/22 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
No verified English name 20 records · Latest accepted 2025/06/17
Supplement · 18Import re-registration · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYSB2500138 | Supplement | 2025/06/17 | Pfizer Europe MA EEIG; Pfizer Manufacturing Belgium NV | CDE ↗ |
| JYSB2500137 | Supplement | 2025/06/17 | Pfizer Europe MA EEIG; Pfizer Manufacturing Belgium NV | CDE ↗ |
| JYSB2400204 | Supplement | 2024/09/05 | Pfizer Europe MA EEIG; Pfizer Manufacturing Belgium NV | CDE ↗ |
| JYSB2400203 | Supplement | 2024/09/05 | Pfizer Europe MA EEIG; Pfizer Manufacturing Belgium NV | CDE ↗ |
| JYSZ2400011 | Import re-registration | 2024/02/01 | Pfizer Europe MA EEIG; Pfizer Manufacturing Belgium NV; Pfizer Investment Co. Ltd. | CDE ↗ |
| JYSZ2400010 | Import re-registration | 2024/02/01 | Pfizer Europe MA EEIG; Pfizer Manufacturing Belgium NV; Pfizer Investment Co. Ltd. | CDE ↗ |
| JYSB2300215 | Supplement | 2023/12/14 | Pfizer Europe MA EEIG; Pfizer Manufacturing Belgium NV | CDE ↗ |
| JYSB2300214 | Supplement | 2023/12/14 | Pfizer Europe MA EEIG; Pfizer Manufacturing Belgium NV | CDE ↗ |
| JYSB2300169 | Supplement | 2023/09/23 | Pfizer Europe MA EEIG; Pfizer Manufacturing Belgium NV | CDE ↗ |
| JYSB2300168 | Supplement | 2023/09/23 | Pfizer Europe MA EEIG; Pfizer Manufacturing Belgium NV | CDE ↗ |
| JYSB2200059 | Supplement | 2022/03/28 | Pfizer Europe MA EEIG; Pfizer Manufacturing Belgium NV | CDE ↗ |
| JYSB2200058 | Supplement | 2022/03/28 | Pfizer Europe MA EEIG; Pfizer Manufacturing Belgium NV | CDE ↗ |
| JYSB2101144 | Supplement | 2021/10/11 | Pfizer Europe MA EEIG; Pfizer Manufacturing Belgium NV | CDE ↗ |
| JYSB2101143 | Supplement | 2021/10/11 | Pfizer Europe MA EEIG; Pfizer Manufacturing Belgium NV | CDE ↗ |
| JYSB2101085 | Supplement | 2021/07/09 | Pfizer Europe MA EEIG; Pfizer Manufacturing Belgium NV | CDE ↗ |
| JYSB2101084 | Supplement | 2021/07/09 | Pfizer Europe MA EEIG; Pfizer Manufacturing Belgium NV | CDE ↗ |
| JYSB2100051 | Supplement | 2021/02/23 | Pfizer Europe MA EEIG; Pfizer Manufacturing Belgium NV | CDE ↗ |
| JYSB2100050 | Supplement | 2021/02/23 | Pfizer Europe MA EEIG; Pfizer Manufacturing Belgium NV | CDE ↗ |
| JYSB2100021 | Supplement | 2021/01/16 | Pfizer Europe MA EEIG; Pfizer Manufacturing Belgium NV | CDE ↗ |
| JYSB2100020 | Supplement | 2021/01/16 | Pfizer Europe MA EEIG; Pfizer Manufacturing Belgium NV | CDE ↗ |
No verified English name 16 records · Latest accepted 2025/01/04
Supplement · 12Import re-registration · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYSB2500007 | Supplement | 2025/01/04 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2500006 | Supplement | 2025/01/04 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2500005 | Supplement | 2025/01/04 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2500004 | Supplement | 2025/01/04 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSZ2200036 | Import re-registration | 2022/07/21 | Pfizer Europe MA EEIG; Wyeth Farma S.A.; Pfizer Investment Co. Ltd. | CDE ↗ |
| JYSZ2200035 | Import re-registration | 2022/07/21 | Pfizer Europe MA EEIG; Wyeth Farma S.A.; Pfizer Investment Co. Ltd. | CDE ↗ |
| JYSZ2200034 | Import re-registration | 2022/07/21 | Pfizer Europe MA EEIG; Wyeth Farma S.A.; Pfizer Investment Co. Ltd. | CDE ↗ |
| JYSZ2200033 | Import re-registration | 2022/07/21 | Pfizer Europe MA EEIG; Wyeth Farma S.A.; Pfizer Investment Co. Ltd. | CDE ↗ |
| JYSB2101103 | Supplement | 2021/08/10 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2101102 | Supplement | 2021/08/10 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2101101 | Supplement | 2021/08/10 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2101100 | Supplement | 2021/08/10 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2100048 | Supplement | 2021/02/19 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2100047 | Supplement | 2021/02/19 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2100046 | Supplement | 2021/02/19 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| JYSB2100045 | Supplement | 2021/02/19 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
Dacomitinib Tablets 10 records · Latest accepted 2025/01/01
Supplement · 8Import re-registration · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2400694 | Supplement | 2025/01/01 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| JYHB2400693 | Supplement | 2025/01/01 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| JYHZ2300398 | Import re-registration | 2023/10/13 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH; Pfizer Investment CO. Ltd. | CDE ↗ |
| JYHZ2300397 | Import re-registration | 2023/10/13 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH; Pfizer Investment CO. Ltd. | CDE ↗ |
| JYHB2300482 | Supplement | 2023/08/29 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| JYHB2300481 | Supplement | 2023/08/29 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| JYHB2101388 | Supplement | 2021/09/01 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| JYHB2101387 | Supplement | 2021/09/01 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| JYHB2101073 | Supplement | 2021/05/13 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| JYHB2101072 | Supplement | 2021/05/13 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
Axitinib Tablets 6 records · Latest accepted 2024/08/16
Import · 2Import re-registration · 2Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHS2400055 | Import | 2024/08/16 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH; Pfizer Investment Co. Ltd. | CDE ↗ |
| JXHS2400054 | Import | 2024/08/16 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH; Pfizer Investment Co. Ltd. | CDE ↗ |
| JYHZ2400105 | Import re-registration | 2024/05/07 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH; Pfizer Investment Co. Ltd | CDE ↗ |
| JYHZ2400104 | Import re-registration | 2024/05/07 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH; Pfizer Investment Co. Ltd | CDE ↗ |
| JYHB2101026 | Supplement | 2021/04/10 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg | CDE ↗ |
| JYHB2101025 | Supplement | 2021/04/10 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg | CDE ↗ |
Tafamidis Meglumine Soft Capsules 6 records · Latest accepted 2024/02/08
Import re-registration · 1Supplement · 5
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2400044 | Import re-registration | 2024/02/08 | Pfizer Europe MA EEIG; Catalent Pharma Solutions LLC; Pfizer Investment Co. Ltd. | CDE ↗ |
| JYHB2300759 | Supplement | 2023/12/30 | Pfizer Europe MA EEIG; Catalent Pharma Solutions LLC | CDE ↗ |
| JYHB2300503 | Supplement | 2023/09/06 | Pfizer Europe MA EEIG; Catalent Pharma Solutions LLC | CDE ↗ |
| JYHB2300285 | Supplement | 2023/05/11 | Pfizer Europe MA EEIG; Catalent Pharma Solutions LLC | CDE ↗ |
| JYHB2300058 | Supplement | 2023/01/20 | Pfizer Europe MA EEIG; Catalent Pharma Solutions LLC | CDE ↗ |
| JYHB2101510 | Supplement | 2021/11/08 | Pfizer Europe MA EEIG; Catalent Pharma Solutions LLC | CDE ↗ |
No verified English name 1 records · Latest accepted 2023/11/17
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHS2300103 | Import | 2023/11/17 | Pfizer Europe MA EEIG; Hospira Australia Pty Ltd; Pfizer Investment Co. Ltd. | CDE ↗ |
No verified English name 4 records · Latest accepted 2021/07/14
Import · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHS2101032 | Import | 2021/07/14 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH; Pfizer Investment Co. Ltd. | CDE ↗ |
| JXHS2101031 | Import | 2021/07/14 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH; Pfizer Investment Co. Ltd. | CDE ↗ |
| JXHS2101003 | Import | 2021/04/15 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH; Pfizer Investment Co. Ltd. | CDE ↗ |
| JXHS2101002 | Import | 2021/04/15 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH; Pfizer Investment Co. Ltd. | CDE ↗ |
Changes in the last 90 days
13 events from 2026/08/14 to 2026/11/11. CDE data as of 2026/11/11 06:42; NMPA data as of 2026/11/10 18:31.
This source was last successfully updated at 2026/11/10 18:31; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Accepted: 8 applicationsNo longer listed under review: 5 applications
- 2026/11/09Accepted
Voriconazole for Injection
JYHZ2600296
Fact date: 2026/11/09 · Site observation date: 2026/11/10
View source ↗ - 2026/11/04No longer listed under review
No verified English name
JXSL2600227
Fact date: 2026/11/04 · Site observation date: 2026/11/04
Accepted: 2026/08/24
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/11/04No longer listed under review
No verified English name
JXSL2600226
Fact date: 2026/11/04 · Site observation date: 2026/11/04
Accepted: 2026/08/24
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/11/04No longer listed under review
No verified English name
JXSL2600221
Fact date: 2026/11/04 · Site observation date: 2026/11/04
Accepted: 2026/08/21
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/10/31No longer listed under review
Tafamidis soft Capsules
JYHB2600018
Fact date: 2026/10/31 · Site observation date: 2026/10/31
Accepted: 2026/01/06
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/10/29No longer listed under review
No verified English name
JYSB2600234
Fact date: 2026/10/29 · Site observation date: 2026/10/29
Accepted: 2026/08/24
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/09/28Accepted
No verified English name
JYHZ2600244
Fact date: 2026/09/28 · Site observation date: 2026/10/22
View source ↗ - 2026/09/28Accepted
No verified English name
JYHZ2600243
Fact date: 2026/09/28 · Site observation date: 2026/10/22
View source ↗ - 2026/08/31Accepted
Tofacitinib Citrate Tablets
JYHB2600502
Fact date: 2026/08/31 · Site observation date: 2026/10/22
View source ↗ - 2026/08/24Accepted
No verified English name
JYSB2600234
Fact date: 2026/08/24 · Site observation date: 2026/10/22
View source ↗ - 2026/08/24Accepted
No verified English name
JXSL2600227
Fact date: 2026/08/24 · Site observation date: 2026/10/22
View source ↗ - 2026/08/24Accepted
No verified English name
JXSL2600226
Fact date: 2026/08/24 · Site observation date: 2026/10/22
View source ↗ - 2026/08/21Accepted
No verified English name
JXSL2600221
Fact date: 2026/08/21 · Site observation date: 2026/10/22
View source ↗
Under review
17 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/11 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Voriconazole for Injection | JYHZ2600296 | Import re-registration | 2026/11/09 | Pfizer Europe MA EEIG; Pharmacia & Upjohn Company LLC; Pfizer Investment CO. Ltd. | CDE ↗ |
| No verified English name | JYHZ2600244 | Import re-registration | 2026/09/28 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH; Pizer Investment Co. Ltd. | CDE ↗ |
| No verified English name | JYHZ2600243 | Import re-registration | 2026/09/28 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH; Pizer Investment Co. Ltd. | CDE ↗ |
| Tofacitinib Citrate Tablets | JYHB2600502 | Supplement | 2026/08/31 | Pfizer Europe MA EEIG; Pfizer Manufacturing Deutschland GmbH | CDE ↗ |
| Parecoxib Sodium for Injection | JYHZ2600191 | Import re-registration | 2026/08/12 | Pfizer Europe MA EEIG; Pharmacia & Upjohn Company LLC; Pfizer Investment CO. Ltd. | CDE ↗ |
| No verified English name | JXHS2600071 | Import | 2026/06/22 | Pfizer Europe MA EEIG; Excella GmbH & Co. KG; Pfizer Investment CO. Ltd. | CDE ↗ |
| No verified English name | JXHS2600070 | Import | 2026/06/22 | Pfizer Europe MA EEIG; Excella GmbH & Co. KG; Pfizer Investment CO. Ltd. | CDE ↗ |
| No verified English name | JXHS2600069 | Import | 2026/06/22 | Pfizer Europe MA EEIG; Excella GmbH & Co. KG; Pfizer Investment CO. Ltd. | CDE ↗ |
| No verified English name | JXHS2600068 | Import | 2026/06/22 | Pfizer Europe MA EEIG; Excella GmbH & Co. KG; Pfizer Investment CO. Ltd. | CDE ↗ |
| No verified English name | JYHB2600251 | Supplement | 2026/05/08 | Pfizer Europe MA EEIG; Pfizer Ireland Pharmaceuticals Unlimited Company | CDE ↗ |
| No verified English name | JYHB2600189 | Supplement | 2026/03/21 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| No verified English name | JYHB2600188 | Supplement | 2026/03/21 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| No verified English name | JYHB2600187 | Supplement | 2026/03/21 | Pfizer Europe MA EEIG; Pfizer Italia S.r.l. | CDE ↗ |
| No verified English name | JYSB2500251 | Supplement | 2025/10/21 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| No verified English name | JYSB2500250 | Supplement | 2025/10/21 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| No verified English name | JYSB2500249 | Supplement | 2025/10/21 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
| No verified English name | JYSB2500248 | Supplement | 2025/10/21 | Pfizer Europe MA EEIG; Wyeth Farma S.A. | CDE ↗ |
Catalogue holder records
1 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/11 06:38. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Tafamidis Meglumine Soft Capsules | Pfizer Europe MA EEIG | Catalent Pharma Solutions, LLC | H20200001 | 2020/02/05 | Imported originator drug | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
0 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/11 06:40.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
10 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/11 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No verified English name | JTS2600125 | Not stated by source | 2026/07/22 | Pfizer Ireland Pharmaceuticals Unlimited Company; Pfizer Europe MA EEIG; Hui Rui Investment Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2300097 | Not stated by source | 2023/04/11 | Hospira Australia Pty Ltd; Pfizer Europe MA EEIG; Hui Rui Investment Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2200226 | Not stated by source | 2022/11/14 | Excella GmbH & Co. KG; Pfizer Europe MA EEIG; Hui Rui Investment Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2200225 | Not stated by source | 2022/11/14 | Excella GmbH & Co. KG; Pfizer Europe MA EEIG; Hui Rui Investment Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2200223 | Not stated by source | 2022/11/14 | Excella GmbH & Co. KG; Pfizer Europe MA EEIG; Hui Rui Investment Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2200224 | Not stated by source | 2022/11/12 | Excella GmbH & Co. KG; Pfizer Europe MA EEIG; Hui Rui Investment Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2100068 | Not stated by source | 2021/03/12 | Pfizer Manufacturing Deutschland GmbH; Pfizer Europe MA EEIG; Hui Rui Investment Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2100067 | Not stated by source | 2021/03/12 | Pfizer Manufacturing Deutschland GmbH; Pfizer Europe MA EEIG; Hui Rui Investment Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2100018 | Not stated by source | 2021/02/05 | Pfizer Manufacturing Deutschland GmbH; Pfizer Europe MA EEIG; Hui Rui Investment Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2100017 | Not stated by source | 2021/02/05 | Pfizer Manufacturing Deutschland GmbH; Pfizer Europe MA EEIG; Hui Rui Investment Co., Ltd. romanized | CDE ↗ |
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/11 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/11 06:38
- Full API register
- Last successful update: 2026/11/11 06:40
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31 · Current coverage may be incomplete
First index-page publication dates: — to —; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Drug names use verified official English names only. Missing names are shown as No verified English name, linking to a Chinese page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized. Original statutory reference numbers are the sole visible Chinese exception.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Chinese free text is not displayed; use the source links or source-name columns in CSV exports.